Lophenol 是一种具有口服活性的植物甾醇及 PPARα 和 PPARγ 激活剂,可抑制脂肪堆积、体重增加、肝脏甘油三酯蓄积及血清脂质升高,调控肝脏脂质与糖代谢相关基因的表达并下调肝脏脂质相关基因的表达,恢复抗氧化酶浓度与肝功能指标水平并改善肝组织损伤,可用于饮食诱导肥胖、药物性肝损伤、甾醇代谢及线虫发育调控的相关研究。
产品编号: MS-V48353 CAS No.: 481-25-4 分子式: C28H48O 分子量: 400.68
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Lophenol 是一种具有口服活性的植物甾醇及 PPARα 和 PPARγ 激活剂,可抑制脂肪堆积、体重增加、肝脏甘油三酯蓄积及血清脂质升高,调控肝脏脂质与糖代谢相关基因的表达并下调肝脏脂质相关基因的表达,恢复抗氧化酶浓度与肝功能指标水平并改善肝组织损伤,可用于饮食诱导肥胖、药物性肝损伤、甾醇代谢及线虫发育调控的相关研究。

生物实验数据

生物活性 Lophenol is an orally active phytosterol and PPARα and PPARγ activator that inhibits fat accumulation, body weight gain, hepatic triglyceride accumulation, and serum lipid elevation, regulates the expression of genes related to hepatic lipid and glucose metabolism while downregulating hepatic lipid-related gene expression, restores antioxidant enzyme concentrations and liver function marker levels and ameliorates liver tissue damage, and can be used in research related to diet-induced obesity, drug-induced liver injury, sterol metabolism, and nematode developmental regulation.
IC50 & Target

PPARα

 

PPARγ

 

体外研究
(In Vitro)

Lophenol (10-50 μM; 16 h) 是一种弱激动剂,可在 CV1 细胞中呈剂量依赖性激活 PPARα 和 PPARγ 的转录活性,而对 PPARδ 的影响极小。

Real Time qPCR

Cell Line: CV1 Cell
Concentration: 10 μM; 50 μM
Incubation Time: 16 h
Result: Acted as a weak agonist that dose-dependently activated the transcriptional activities of PPARα and PPARγ in CV1 cells, while exerting minimal effects on PPARδ.
体内研究
(In Vivo)

Lophenol (1 µg/只/天;口服;每日给药;持续 12 周) 可降低饮食诱导肥胖雄性 C57BL/6J 小鼠的体重增长、体脂蓄积以及肝脏和血清脂质指标,同时通过调控 PPAR 靶基因表达来改善脂肪酸代谢。
Lophenol (腹腔注射;每日 1 次,连续 7 天,剂量 25-50 μg/kg BW) 对瑞士白化小鼠中对 Acetaminophen (MS-H20928) 诱导的肝损伤表现出剂量依赖性的保肝活性,其中 50 μg/kg BW 剂量可使肝功能标志物、抗氧化酶水平及肝脏组织学恢复至接近正常水平。
Lophenol (13 μM) 完全替代培养基中的胆固醇时,可使第二代野生型秀丽隐杆线虫在食物充足和低种群密度条件下形成 dauer 幼虫。加入低至20 nM的 Lathosterol (MS-W16584)可完全阻止该表型,使线虫发育为具有生殖能力的成虫。

Animal Model: C57BL/6J (6-week-old male; diet-induced obesity model)
Dosage: 1 µg/mouse/day
Administration: p.o.; daily; 12 weeks
Result: Reduced body weight to 33.9 g compared to control's 40.3 g (P < 0.01) after 12 weeks; showed non-significant body weight reduction to 29.9 g compared to control's 31.8 g (P > 0.05) after 4 weeks.
Reduced intra-abdominal fat weight to 2.51 g compared to control's 5.44 g (P < 0.01) and subcutaneous fat weight to 2.54 g compared to control's 4.94 g (P < 0.01) after 4 weeks.
Reduced liver triglyceride levels to 66.0 mg/g compared to control's 76.9 mg/g (P < 0.05), serum triglyceride levels to 70.0 mg/dl compared to control's 84.7 mg/dl (P < 0.05), serum non-esterified fatty acid levels to 1.09 mEq/l compared to control's 1.63 mEq/l (P < 0.01), and serum total cholesterol levels to 181.8 mg/dl compared to control's 207.7 mg/dl (P < 0.05) after 4 weeks.
Increased liver mRNA expression of Acsl1 (2.47-fold, P < 0.05), Acaa1a (1.73-fold, P < 0.05), Acox1 (2.34-fold, P < 0.05), Cpt1a (2.82-fold, P < 0.01), Cpt2 (1.66-fold, P < 0.05), Cyp4a10 (4.90-fold, P < 0.01), Cyp4a14 (10.79-fold, P < 0.05), Hmgcs2 (1.98-fold, P < 0.05), Pck1 (3.44-fold, P < 0.05), Fads2 (2.62-fold, P < 0.05), Scd1 (2.89-fold, P < 0.05), Scd2 (1.71-fold, P < 0.05), Pparα (4.93-fold, P < 0.01), and Rxra (3.61-fold, P < 0.01) relative to control.
Increased liver mRNA expression of Fatp1 (2.35-fold, P < 0.05), Pck1 (2.02-fold, P < 0.01), Pparα (2.28-fold, P < 0.05), and Rxra (2.54-fold, P < 0.05), and decreased liver mRNA expression of Fabp1 (0.44-fold, P < 0.01), Acbp (0.33-fold, P < 0.05), ApoCIII (0.41-fold, P < 0.05), and ApoAI (0.34-fold, P < 0.01) relative to control.
Animal Model: Swiss albino mice (healthy young adults, either sex, 8-12 weeks old, 22 g weight)
Dosage: 25 μg/kg BW; 50 μg/kg BW
Administration: i.p.; daily; 7 days
Result: Significantly reduced serum ALT, AST, ALP, LDH, and direct bilirubin (2.9) levels relative to the acetaminophen-only group at 25 μg/kg BW.
Significantly increased hepatic SOD, CAT, and GSH levels relative to the acetaminophen-only group at 25 μg/kg BW.
Showed mild hemorrhages, mild fatty changes, and mild inflammatory infiltrate, with no karyolysis in liver histology at 25 μg/kg BW.
Significantly reduced serum ALT, AST, ALP, LDH, and direct bilirubin levels relative to the acetaminophen-only group at 50 μg/kg BW.
Significantly increased hepatic SOD, CAT, and levels relative to the acetaminophen-only group at 50 μg/kg BW.
Showed mild hemorrhages, with no karyolysis, fatty changes, or inflammatory infiltrate in liver histology at 50 μg/kg BW.
All changes were statistically significant at p < 0.001 compared to the acetaminophen-only group, except for CAT (p < 0.05) and GSH (p < 0.01) at the 25 μg/kg BW dose.

化学信息

分子量 400.68
分子式 C28H48O
CAS No. 481-25-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础